Etoposide

Generic Name: Etoposide

Brand Names: Etopophos, Toposar, Vepesid

Drug Type: Small Molecule

Chemical Formula: C_₂₉H_₃₂O_₁₃

CAS Number: 33419-42-0

Unique Ingredient Identifier: 6PLQ3CP4P3

Background: A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to ce...

Indication: For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer

Associated Therapies: -

Clinical Trials

Brentuximab Vedotin in Combination With CHEP in Patient With PTCL

Phase 2

Not yet recruiting

Conditions: Lymphoma, T-Cell, Peripheral

Interventions: Drug: Adcetris 50 MG Injection
Drug: Endoxan
Drug: Doxorubicin
Drug: Etoposide
Drug: Prednisone tablet

First Posted Date: 2021-08-16

Last Posted Date: 2021-09-01

Lead Sponsor: Czech Lymphoma Study Group

Target Recruit Count: 33

Registration Number: NCT05006664

Locations: 🇨🇿
University Hospital Olomouc, Olomouc, Czechia
🇨🇿
University Hospital Plzeň, Plzeň, Czechia
🇨🇿
University Hospital Brno, Brno, Czechia

and more 4 locations

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Phase 2

Withdrawn

Conditions: Stage IIB Lung Cancer AJCC v8
Lung Non-Small Cell Carcinoma
Superior Sulcus Lung Carcinoma
Stage IIIA Lung Cancer AJCC v8

Interventions: Biological: Atezolizumab
Procedure: Biopsy
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Drug: Cisplatin
Drug: Etoposide
Radiation: External Beam Radiation Therapy
Procedure: Magnetic Resonance Imaging
Drug: Paclitaxel
Drug: Pemetrexed
Procedure: Positron Emission Tomography
Procedure: Therapeutic Conventional Surgery

First Posted Date: 2021-08-04

Last Posted Date: 2023-09-26

Lead Sponsor: National Cancer Institute (NCI)

Registration Number: NCT04989283

Locations: 🇺🇸
Community Medical Hospital, Missoula, Montana, United States
🇺🇸
The Mark H Zangmeister Center, Columbus, Ohio, United States
🇺🇸
Rush - Copley Medical Center, Aurora, Illinois, United States

and more 43 locations

A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide (NICE-40) in Patients With Relapsed/Refractory Hodgkin Lymphoma

Phase 1

Recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: Nivolumab
Drug: Ifosfamide
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2021-07-29

Last Posted Date: 2023-04-12

Lead Sponsor: St. Petersburg State Pavlov Medical University

Target Recruit Count: 30

Registration Number: NCT04981899

Locations: 🇷🇺
St. Petersburg State Pavlov Medical University, Saint Petersburg, Russian Federation
🇷🇺
Irkutsk Regional Cancer Center, Irkutsk, Russian Federation
🇷🇺
National Medicine Research Center of oncology named after N.N. Petrov, Saint Petersburg, Pesochny, Russian Federation

A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer

Phase 2

Terminated

Conditions: Small-cell Lung Cancer

Interventions: Drug: Carboplatin
Drug: Cisplatin
Drug: Etoposide
Drug: Durvalumab
Radiation: Stereotactic Body Radiotherapy

First Posted Date: 2021-07-06

Last Posted Date: 2024-11-26

Lead Sponsor: Weill Medical College of Cornell University

Target Recruit Count: 6

Registration Number: NCT04951115

Locations: 🇺🇸
New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, New York, United States
🇺🇸
Weill Cornell Medicine, New York, New York, United States
🇺🇸
New York-Presbyterian Queens, Flushing, New York, United States

A Study of N9 Chemotherapy in Children With Neuroblastoma

Early Phase 1

Active, not recruiting

Conditions: Pediatric Cancer
Neuroblastoma

Interventions: Drug: Cyclophosphamide
Drug: Topotecan
Drug: Vincristine
Drug: Doxorubicin
Drug: Ifosfamide
Drug: Etoposide
Drug: Carboplatin
Drug: Mesna

First Posted Date: 2021-07-01

Last Posted Date: 2024-12-02

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 26

Registration Number: NCT04947501

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas

First Posted Date: 2021-06-22

Last Posted Date: 2024-07-09

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 8

Registration Number: NCT04933617

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)

Phase 2

Active, not recruiting

Conditions: Small Cell Lung Cancer

Interventions: Biological: Pembrolizumab
Drug: Lenvatinib
Biological: MK-4830
Biological: Boserolimab
Drug: Etoposide
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2021-06-11

Last Posted Date: 2024-11-19

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 120

Registration Number: NCT04924101

Locations: 🇺🇸
UPMC Hillman Cancer Center ( Site 0127), Pittsburgh, Pennsylvania, United States
🇺🇸
MFSMC-HJWCI-Oncology Research ( Site 0128), Baltimore, Maryland, United States
🇺🇸
Cleveland Clinic-Taussig Cancer Center ( Site 0116), Cleveland, Ohio, United States

and more 46 locations